NIPT is a non-invasive prenatal DNA test developed for the screening of fetal chromosomal abnormalities, such as Down syndrome, Edwards syndrome (trisomy 18) and Patau syndrome (trisomy 13). The test is based on proprietary technologies developed at The Chinese University of Hong Kong.

During pregnancy, the unborn child releases some of its DNA into the blood circulation of its mother. NIPT is a test that measures the amount of DNA molecules from chromosomes 21, 18, 13 and others in the blood samples of pregnant women.


NIPT Procedures:

- An ultrasound examination to measure the size of the fetus and determinate the gestation
- Blood taking from pregnant women for assessment

“Positive” results:

Do not 100% confirm that the baby is affected with chromosomal abnormality. There is a chance of a false positive result. So, positive test results should be confirmed by amniocentesis or chorionic villus sampling.

“Negative” results:
The chance of baby affected with Down ‘s syndrome, trisomy 18, trisomy 13, sex chromosomal abnormalities and common microdeletion syndrome is very low. However, it is also important to point out that safe T21 remains a screening test. It cannot completely exclude the possibility of having a baby with these chromosome abnormalities. So Invasive testing (eg. amniocentesis or chorionic villus sampling) may sometimes be necessary to confirm the diagnosis. References: